Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of pegylated recombinant human arginase for treatment of leukemia

A technology of pegylation and arginase, which can be applied to medical preparations without active ingredients, medical preparations containing active ingredients, and drug combinations, and can solve problems such as poor prognosis

Inactive Publication Date: 2013-11-20
BIO CANCER TREATMENT INT
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients may be considered for clinical trials or given palliative care, in both cases the prognosis is very poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of pegylated recombinant human arginase for treatment of leukemia
  • Use of pegylated recombinant human arginase for treatment of leukemia
  • Use of pegylated recombinant human arginase for treatment of leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Inhibitory effect of BCT-100 on various leukemia cell lines

[0035] The inhibitory effect of BCT-100 in acute myeloid leukemia cells (Kasumi-la, ML2, HL60, K562 and NB4) and T cell leukemia cells (Jurkat, ALL-SIL, HPB-ALL and TALL-1) was studied. IC of BCT-100 in various cell lines 50 Values ​​are shown in Table 1. The results showed that BCT-100 effectively inhibited the growth of leukemia, including myeloid leukemia and lymphocytic leukemia.

[0036] Table 1: IC of BCT-100 in various cell lines 50

[0037] myeloid leukemia

Embodiment 2

[0039] Effects of BCT-100 on arsenic-sensitive and arsenic-resistant myeloid cell lines

[0040] The effect of BCT-100 was studied on arsenic-sensitive myeloid cell lines (NB4 and U937) and arsenic-resistant myeloid cell lines (HL60 and UF1). Figure 1a Shows the effect of arsenic trioxide on cell viability in myeloid cell lines. As the arsenic concentration increased, the cell viability of the arsenic-sensitive NB4 and U937 cell lines decreased. However, HL60 and UF1 cell lines were not sensitive to As 2 o 3 Handling reacts.

[0041] Figure 1b The effect of BCT-100 on the cell viability of the myeloid cell lines NB4, U937, HL60 and UF1 is shown. Both arsenic-sensitive and resistant leukemia cells responded to BCT-100 treatment. In all cases, cell viability decreased as the amount of BCT-100 in the medium increased.

[0042] The results showed that BCT-100 effectively inhibited the growth of myeloid leukemia, including arsenic-resistant myeloid leukemia. Therefore, the...

Embodiment 3

[0044] Effect of BCT-100 on Inducing Apoptosis in Leukemia Cells

[0045] The effect of BCT-100 on the induction of apoptosis in arsenic-sensitive (NB4 and U937) and arsenic-resistant (HL60 and UF1) leukemia cell lines was tested. Such as figure 2 As shown, arsenic effectively induces apoptosis in the leukemia cell lines NB4 and U937. However, since these cell lines are arsenic-resistant, the rate of apoptosis in HL60 and UF1 cells was low in the presence of arsenic. BCT-100 was found to be effective in inducing apoptosis in arsenic-sensitive and arsenic-resistant leukemia cell lines. When BCT-100 was combined with arsenic trioxide, the rate of cell apoptosis was further enhanced.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for treatment of leukemia comprising administration of arginase to a subject in need thereof. In one embodiment, the leukemia is lymphocytic or myeloid. In another embodiment, the leukemia is arsenic resistant. In a further embodiment, the arginase is pegylated recombinant human arginase. In another embodiment, the arginase can be administrated in combination with a second therapeutic agent such as Doxorubicin in the treatment of leukemia.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61 / 425,243 filed December 21, 2010, the entire contents of which are hereby incorporated by reference. technical field [0003] The invention relates to a method for using arginase to treat leukemia, specifically, the method relates to treating leukemia with pegylated recombinant human arginase. Background technique [0004] Hematologic malignancies, such as non-Hodgkin's lymphoma and leukemia, rank as the 10 most common cancers worldwide. Acute lymphoblastic leukemia is one of the most common pediatric malignancies and, despite high cure rates achieved by current treatment options, remains the leading cause of childhood mortality from the disease. In adults, hematological malignancies account for approximately 10 percent of all cancers. Chemotherapy and targeted therapy are still the mainstream of treatment. Once relapse oc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/50A61K47/48A61P35/02
CPCA61K38/50A61K47/48215A61K31/704A61K47/60A61P35/02A61K2300/00
Inventor 郑宁民
Owner BIO CANCER TREATMENT INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com